133 related articles for article (PubMed ID: 6295596)
1. Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with adriamycin.
Melia WM; Johnson PJ; Williams R
Cancer; 1983 Jan; 51(2):206-10. PubMed ID: 6295596
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of VP-16 and the combination of adriamycin and vincristine in advanced breast cancer.
Eagan RT; Ahmann DL; Bisel HF
Oncology; 1976; 33(3):146-8. PubMed ID: 1012648
[TBL] [Abstract][Full Text] [Related]
3. [Therapeutic results using VP 16-213 alone or in combination with 5-fluorouracil in liver cancer (hepatoma)].
Cavalli F; Tschopp L; Gerber A; Sonntag RW; Ryssel HJ; Brunner KW
Schweiz Med Wochenschr; 1977 Dec; 107(52):1960-6. PubMed ID: 202020
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of oral VP-16-213 in hepatocellular carcinoma.
Cavalli F; Rozencweig M; Renard J; Goldhirsch A; Hansen HH
Eur J Cancer Clin Oncol; 1981 Oct; 17(10):1079-82. PubMed ID: 6279406
[No Abstract] [Full Text] [Related]
5. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial.
Lai CL; Wu PC; Chan GC; Lok AS; Lin HJ
Cancer; 1988 Aug; 62(3):479-83. PubMed ID: 2839280
[TBL] [Abstract][Full Text] [Related]
6. Epipodophyllin derivative (VP 16-213) in treatment of solid tumours.
Cavalli F; Sonntag RW; Brunner KW
Lancet; 1977 Aug; 2(8033):362. PubMed ID: 69974
[No Abstract] [Full Text] [Related]
7. [Experiences with VP-16 in combination with cyclophosphamide or adriamycin in the anaplastic, predominantly small cell bronchogenic carcinoma].
Schmieder HA; Jungi WF; Mayr AC; Senn HJ
Schweiz Med Wochenschr; 1979 Jun; 109(22):841-4. PubMed ID: 462156
[TBL] [Abstract][Full Text] [Related]
8. Combination chemotherapy of hepatocellular cancer. Comparison of adriamycin + VM 26 + 5-fluorouracil with mAMSA + VM 26 + 5-fluorouracil.
Bezwoda WR; Weaving A; Kew M; Derman DP
Oncology; 1987; 44(4):207-9. PubMed ID: 3039431
[TBL] [Abstract][Full Text] [Related]
9. Oral VP-16-213 in advanced bronchogenic carcinoma and toxic effects when combined with methotrexate.
Anderson G; Bowyer F; Williams L
Thorax; 1981 Jun; 36(6):462-4. PubMed ID: 7314017
[TBL] [Abstract][Full Text] [Related]
10. Adriamycin and VP16-213 combination treatment for breast cancer previously treated by the CMF regimen.
Perez Manga G; Madrigal Alonso P; Alburquerque Carbuccia H
Cancer Chemother Pharmacol; 1982; 7(2-3):231-3. PubMed ID: 6896298
[No Abstract] [Full Text] [Related]
11. A phase II study of etoposide in patients with hepatocellular carcinoma by the Tokyo Liver Cancer Chemotherapy Study Group.
Yoshino M; Okazaki N; Yoshida T; Kanda Y; Miki M; Oda H; Sasagawa Y; Hayashi S; Hashimoto N
Jpn J Clin Oncol; 1989 Jun; 19(2):120-2. PubMed ID: 2471845
[TBL] [Abstract][Full Text] [Related]
12. Treatment of hepatocellular carcinoma with adriamycin. Preliminary communication.
Olweny CL; Toya T; Katongole-Mbidde E; Mugerwa J; Kyalwazi SK; Cohen H
Cancer; 1975 Oct; 36(4):1250-7. PubMed ID: 169983
[TBL] [Abstract][Full Text] [Related]
13. Induction of remission in hepatocellular carcinoma with doxorubicin.
Johnson PJ; Williams R; Thomas H; Sherlock S; Murray-Lyon IM
Lancet; 1978 May; 1(8072):1006-9. PubMed ID: 76932
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy.
Choi TK; Lee NW; Wong J
Cancer; 1984 Feb; 53(3):401-5. PubMed ID: 6198058
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival and complete response to adriamycin and etoposide in a case of hepatocellular carcinoma.
Giaccone G; Bonardi G; Leria G; Donadio M; Calciati A
Tumori; 1986 Aug; 72(4):409-11. PubMed ID: 3020753
[TBL] [Abstract][Full Text] [Related]
16. VP-16-213 in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in the treatment of non-Hodgkin's lymphomas.
Hansen MM; Bloomfield CD; Jørgensen J; Ersbøll J; Pedersen-Bjergaard J; Blom J; Nissen NI
Cancer Treat Rep; 1980; 64(10-11):1135-7. PubMed ID: 7459900
[TBL] [Abstract][Full Text] [Related]
17. Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma.
Schmidinger M; Wenzel C; Locker GJ; Muehlbacher F; Steininger R; Gnant M; Crevenna R; Budinsky AC
Br J Cancer; 2001 Dec; 85(12):1850-2. PubMed ID: 11747325
[TBL] [Abstract][Full Text] [Related]
18. [Etoposide. A new highly effective cytostatic agent in anaplastic small-cell bronchial carcinoma, other solid tumors and hemoblastoses].
Goldhirsch A; Joss R; Cavalli F; Sonntag RW; Ryssel HJ; Brunner KW
Dtsch Med Wochenschr; 1981 Aug; 106(35):1105-9. PubMed ID: 6266800
[No Abstract] [Full Text] [Related]
19. VP-16-213 versus polychemotherapy in patients with advanced small cell lung cancer.
Eagan RT; Carr DT; Frytak S; Rubin J; Lee RE
Cancer Treat Rep; 1976 Jul; 60(7):949-51. PubMed ID: 64298
[No Abstract] [Full Text] [Related]
20. [Randomized phase II study with VP-16-213 (etoposide) in the treatment of advanced breast cancer].
Cavalli F; Jungi WF; Brunner KW
Onkologie; 1981 Apr; 4(2):80-3. PubMed ID: 7022286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
